Cyrus J. Lawrence LLC Cuts Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Cyrus J. Lawrence LLC significantly reduced its stake in Thermo Fisher Scientific by 94.0%, owning only 803 shares after selling 12,472 shares during the 1st quarter.
• The company's recent earnings report showed earnings per share of $5.36, exceeding analyst expectations, with projected Q3 2025 EPS guidance between $5.460 and $5.510.
• Thermo Fisher's quarterly dividend of $0.43 will be paid on October 15th, with a 0.3% yield and a current payout ratio of 9.95%.

Cyrus J. Lawrence LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 94.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 803 shares of the medical research company's stock after selling 12,472 shares during the quarter. Cyrus J. Lawrence LLC's holdings in Thermo Fisher Scientific were worth $399,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. MAI Capital Management lifted its stake in Thermo Fisher Scientific by 75.9% during the 1st quarter. MAI Capital Management now owns 39,577 shares of the medical research company's stock valued at $19,694,000 after acquiring an additional 17,071 shares during the period. Saudi Central Bank bought a new position in Thermo Fisher Scientific during the 1st quarter valued at about $75,000. Brasada Capital Management LP bought a new position in Thermo Fisher Scientific during the 1st quarter valued at about $4,505,000. Vident Advisory LLC lifted its stake in Thermo Fisher Scientific by 23.5% during the 1st quarter. Vident Advisory LLC now owns 5,738 shares of the medical research company's stock valued at $2,855,000 after acquiring an additional 1,092 shares during the period. Finally, Parnassus Investments LLC lifted its stake in Thermo Fisher Scientific by 0.7% during the 1st quarter. Parnassus Investments LLC now owns 1,420,431 shares of the medical research company's stock valued at $706,806,000 after acquiring an additional 9,474 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on TMO shares. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research note on Friday, July 11th. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Trading Up 0.7%

Thermo Fisher Scientific stock opened at $493.05 on Friday. The firm has a 50 day moving average of $452.50 and a 200 day moving average of $454.32. The firm has a market capitalization of $186.18 billion, a price-to-earnings ratio of 28.52, a P/E/G ratio of 2.63 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,896 shares of company stock valued at $13,603,438 over the last three months. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.